The need, speed and pricing of the over-night offering
Back to the question … on the CYTX offering … the price bleeding slowed in the after-market to $3.01 down -$0.31 or -9.34% .from one source – this deal once completed is expected to be populated by many fundamental institutions that investors have not seen in their peer group and bridges the funding gap but, there still is the credibility gap to investors. One positive, the BARDA deal is a foundation with most development costs being reimbursed. So is the … Negativity … more likely from people betting on a trading event versus. “investing” in the stock? Underlying fundamentals in the RegMed universe are trial progress, commercial growth and their ability to … access the capital markets – but, at what price?